Continuous Z-Value Metric for Pediatric Septic Shock Endotyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing septic shock in pediatric patients are hindered by patient heterogeneity, making it challenging to determine appropriate therapies and predict outcomes, as existing binary endotyping strategies do not capture the continuum of biological responses to corticosteroids.
Innovation Solution
A continuous metric, the Z value, is used to classify patients based on gene expression patterns, allowing for more precise stratification of risk and tailored treatment approaches by assessing the difference between individual patient mosaics and reference endotypes, incorporating corticosteroid interactions and demographic data.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If binary endotyping strategies are used to classify patients, then treatment decisions can be simplified, but the continuum of biological responses to corticosteroids cannot be captured
Solution Approach 1:
The patent transitions from static binary endotyping (two fixed categories) to a dynamic continuous metric (Z-value) that captures the full spectrum of biological responses. The Z-value calculation dynamically positions patients along a continuum based on gene expression differences, allowing treatment decisions to reflect nuanced biological variability rather than forcing patients into rigid categories.
Solution Approach 2:
The invention changes the parameter of endotype classification from discrete binary values (0 or 1) to a continuous Z-value parameter that can take any value along a spectrum. This parameter transformation enables more precise measurement of biological responses while maintaining mathematical tractability for clinical application.
2Measurement precision
If patient heterogeneity is addressed through detailed stratification, then personalized treatment can be achieved, but measurement and classification complexity increases
Solution Approach 1:
The patent segments the complex task of patient stratification into manageable components: (1) defining reference endotypes based on gene expression profiles, (2) calculating individual patient Z-values by comparing to references, and (3) using Z-value thresholds for classification. This segmentation reduces overall complexity while maintaining high measurement precision.
Solution Approach 2:
The Z-value serves as an intermediary metric that bridges the gap between complex gene expression data and simple treatment decision rules. Instead of directly analyzing hundreds of genes, the Z-value condenses this information into a single continuous parameter that mediates between molecular complexity and clinical simplicity.
3Measurement precision
If continuous metrics are used to assess endotype, then corticosteroid responsiveness can be more accurately predicted, but existing binary classification methods become inadequate
Solution Approach 1:
The continuous Z-value metric dynamically captures varying degrees of corticosteroid responsiveness along a spectrum, allowing treatment strategies to be flexibly adjusted based on individual patient positioning. Patients with Z-values near zero (intermediate position) can be identified as potentially responsive to corticosteroids, while those at extremes can be identified as non-responsive or harmful, providing nuanced adaptability.
Solution Approach 2:
The patent adds a new dimensional perspective to endotype classification by introducing the continuous Z-value dimension. Instead of viewing endotypes as discrete categories, the Z-value creates a gradient dimension that reveals subtle variations in corticosteroid responsiveness, enabling more accurate prediction and flexible treatment adaptation.
Data Source
AI summary
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in patients, such as pediatric. In particular, the invention relates to analyzing biomarkers associated with septic shock in pediatric patients, obtaining a sample from a patient having at least one indication of septic shock, then determining the gene expression mosaic for the patient, wherein the gene expression mosaic can correlate with a predicted outcome and can inform treatment strategy.